You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T-DXd

Showing 1 - 25 of 8,021
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Stomach Tumor Trial (Trastuzumab deruxtecan, Afatinib)

Not yet recruiting
  • Stomach Neoplasm
  • (no location specified)
Oct 16, 2023

Brain Cancer, Glioblastoma, Metastatic Cancer Trial in New York (Trastuzumab deruxtecan)

Recruiting
  • Brain Cancer
  • +4 more
  • Trastuzumab deruxtecan
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Sep 22, 2023

Breast Cancer, Metastatic Breast Cancer Trial (Trastuzumab-Deruxtecan (T-DXd))

Not yet recruiting
  • Breast Cancer
  • Metastatic Breast Cancer
  • Trastuzumab-Deruxtecan (T-DXd)
  • (no location specified)
Sep 20, 2023

Breast Cancer, Brain Metastases, Radiotherapy Trial in Shanghai (Combination use of SRT with T-DXd)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Combination use of SRT with T-DXd
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 14, 2023

T-Dxd in Treatment of HER2-positive BCBM After Prior Pyrotinib

Recruiting
  • Breast Cancer
  • T-DXd
  • Beijing, Beijing, China
  • +1 more
Nov 13, 2023

Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer Trial (T-Dxd(Trastuzmab deruxtecan), Ramucirumab)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction (GEJ) Cancer
  • T-Dxd(Trastuzmab deruxtecan), Ramucirumab
  • (no location specified)
Jun 7, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Metastatic Breast Cancer Trial in Rome (HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and

Recruiting
  • Metastatic Breast Cancer
  • HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
  • Rome, Italy
    Fondazione Policlinico A. Gemelli - IRCCS
Jun 22, 2023

HER2-positive Breast Cancer Trial in Ireland (trastuzumab deruxtecan (T-DXd) (IV))

Not yet recruiting
  • HER2-positive Breast Cancer
  • trastuzumab deruxtecan (T-DXd) (IV)
  • Galway, Connaught, Ireland
  • +4 more
Jan 24, 2023

HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • HER2-positive Gastroesophageal Junction Adenocarcinoma
  • Trastuzumab deruxtecan
  • (no location specified)
Aug 11, 2023

Patients Receiving T-DXd for Treatment of HER2+ Unresectable

Not yet recruiting
  • Breast Cancer
  • None (Observational Study)
  • (no location specified)
Oct 20, 2022

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Kashiwa (Trastuzumab Deruxtecan (T-DXd))

Recruiting
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Trastuzumab Deruxtecan (T-DXd)
  • Kashiwa, Chiba, Japan
    National Cancer Center Hospital East
Apr 5, 2022

DESTINY Breast Respond HER2-low Europe

Not yet recruiting
  • Unresectable Breast Cancer
  • +2 more
  • Trastuzumab deruxtecan
  • (no location specified)
Jul 6, 2023

T-Dxd in Chinese Metastatic HER2-positive Breast Cancer Patients

Active, not recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 25, 2022

Previously Treated Advanced/Metastatic HER2-positive Breast

Recruiting
  • HER2-positive Breast Cancer
  • Trastuzumab deruxtecan
  • Naples, Italy
  • +17 more
Jan 31, 2023

Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Trastuzumab Deruxtecan
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023

Metastatic Cancer Trial in Spain (Tumor and Blood sample collection)

Recruiting
  • Metastatic Cancer
  • Tumor and Blood sample collection
  • Badalona, Barcelona, Spain
  • +14 more
Jan 23, 2023

Breast Cancer Trial in Sweden (Trastuzumab deruxtecan, Docetaxel, Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab deruxtecan
  • +9 more
  • Malmö, Sweden
  • +6 more
Jun 8, 2023

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Trial in China (Trastuzumab Deruxtecan)

Recruiting
  • Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Trastuzumab Deruxtecan
  • Beijing, China
  • +25 more
Jul 27, 2022

Advanced Solid Tumor, Breast Cancer Trial in Atlanta (DS-1103a, T-DXd)

Not yet recruiting
  • Advanced Solid Tumor
  • Breast Cancer
  • Atlanta, Georgia
    Emory University School of Medicine
Mar 1, 2023

HER2 Mutant NSCLC, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation Trial (ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki,

Not yet recruiting
  • HER2 Mutant Non-small Cell Lung Cancer
  • +3 more
  • (no location specified)
Dec 6, 2022

Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric,

Active, not recruiting
  • Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
  • Trastuzumab deruxtecan
  • Santa Rosa, California
  • +29 more
Jun 14, 2022

HER2-mutant NSCLC Trial in China (Trastuzumab deruxtecan)

Recruiting
  • HER2-mutant Non-Small Cell Lung Cancer
  • Trastuzumab deruxtecan
  • Baoding, China
  • +29 more
Jul 20, 2022

Metastatic Breast Cancer Trial in Worldwide (Trastuzumab deruxtecan, Durvalumab, Paclitaxel)

Recruiting
  • Metastatic Breast Cancer
  • Trastuzumab deruxtecan
  • +6 more
  • Iowa City, Iowa
  • +60 more
Jan 3, 2023

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023